证券日报网讯 2月5日，太极实业发布公告称，公司子公司十一科技与上海四建组成联合体，被公示为 华虹宏力半导体（无锡）有限公司华虹FAB9B项目工程总承包拟中标人，投标报价3777540536.50元， 工期350日历天，十一科技预计承担98.46%工作量对应金额约为37.19亿元。 （文章来源：证券日报） ...

Group 1 - Zhenghe Ecology signed a strategic cooperation agreement with the government of Miyun District, Beijing, to provide comprehensive services in water safety, resources, ecology, and technology [2] - GCL-Poly Energy announced that it has not yet received any orders in the "space photovoltaic" sector, which remains in the technical exploration stage with uncertain commercial prospects [3] - Changxin Bochuang's shareholder Zhu Wei terminated the transfer of 5.04% of the company's shares, retaining a total of 7.16% of the company's shares [4] - Tianqimo is planning to acquire equity in Dongshi Automotive Technology Group through a combination of share issuance and cash payment, leading to a suspension of trading [5] Group 2 - Hengwei Technology reported a net profit of 34.938 million yuan for 2025, a year-on-year increase of 30.13%, despite a revenue decline of 6.31% to 1.047 billion yuan [7] - Xianheng International's controlling shareholder and associated parties plan to reduce their holdings by up to 3% of the company's shares [9] - Kangpeng Technology's shareholder Wuxi Yunhui intends to reduce its stake by up to 2.94%, while two other shareholders plan to collectively reduce their holdings by up to 2.28% [10] Group 3 - Southeast Network Framework won a bid for an EPC project worth 994 million yuan [12] - Rongfa Nuclear Power's wholly-owned subsidiary won a project from China General Nuclear Power Corporation valued at 101 million yuan [13] - Taiji Industry's subsidiary is expected to win a bid for the Huahong FAB9B project with a bid amount of 3.778 billion yuan [14]

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

（原标题：太极实业(600667.SH)：子公司十一科技预中标华虹FAB9B项目工程总承包） 格隆汇2月5日丨太极实业(600667.SH)公布，公司子公司信息产业电子第十一设计研究院科技工程股份 有限公司（以下简称"十一科技"）与上海建工四建集团有限公司（以下简称"上海四建"）组成联合体， 参与了华虹宏力半导体（无锡）有限公司的华虹FAB9B项目工程总承包（以下简称"项目"）的投标。根 据无锡市公共资源交易中心发布的《无锡市工程建设项目中标人公示（编号：WXXQ202601001- X01）》（https://ggzyjy.wuxi.gov.cn/doc/2026/02/03/4727873.shtml），十一科技、上海四建组成的联合 体为项目拟确定中标人，本次预中标项目投标报价为人民币37.78亿元，根据《联合体协议书》约定的 分工，预计十一科技合同工作量占比为98.46%，对应金额约为37.19亿元。以上金额占比仅为初步估算 数据，最终实际金额以确定中标后签订的正式合同为准。 ...

智通财经APP讯，太极实业(600667.SH)发布公告，公司子公司十一科技与上海四建组成联合体，参与 了华虹宏力半导体(无锡)有限公司的华虹FAB9B项目工程总承包的投标。根据公示，联合体为项目拟确 定中标人，投标报价为37.78亿元。十一科技为联合体牵头人，预计合同工作量占比为98.46%，金额约 为37.19亿元。 该项目预中标体现了十一科技在国内集成电路产业工程领域的EPC领先地位。如能确定中标并签订正式 合同，因项目存在跨年实施，且受合同签订时间、开工日期及实施进度影响，对公司2026年度业绩的影 响存在不确定性。 ...

该项目预中标体现了十一科技在国内集成电路产业工程领域的EPC领先地位。如能确定中标并签订正式 合同，因项目存在跨年实施，且受合同签订时间、开工日期及实施进度影响，对公司2026年度业绩的影 响存在不确定性。 太极实业（600667）(600667.SH)发布公告，公司子公司十一科技与上海四建组成联合体，参与了华虹 宏力半导体(无锡)有限公司的华虹FAB9B项目工程总承包的投标。根据公示，联合体为项目拟确定中标 人，投标报价为37.78亿元。十一科技为联合体牵头人，预计合同工作量占比为98.46%，金额约为37.19 亿元。 ...

证券代码：600667 证券简称：太极实业 公告编号：临 2026-008 无锡市太极实业股份有限公司 关于累计诉讼、仲裁事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要事项提示： ●案件所处的诉讼阶段：受理阶段 ●上市公司所处的当事人地位：无锡市太极实业股份有限公司（以下简称"公 司"）子公司信息产业电子第十一设计研究院科技工程股份有限公司（以下简称 "十一科技"）及信息产业电子第十一设计研究院科技工程股份有限公司海门分 公司（以下简称"十一科技海门分公司"）为被告。 ●涉案金额：本次诉讼涉案金额包括工程款 1,108.14 万元及资金占用损失。 自公司前次披露累计诉讼、仲裁情况公告后，公司及控股子公司连续十二个月内 未披露的诉讼和仲裁事项累计涉案金额为 85,798.34 万元（含本次诉讼事项）， 占公司最近一期经审计净资产的 10.09%。 ●由于部分诉讼、仲裁案件尚未开庭审理、调解、判决或结案，目前尚不能 确定对公司本期利润或期后利润的影响。公司将根据案件进展情况，按照法律法 规及企业会计准则进行相应会 ...

证券代码：600667 证券简称：太极实业 公告编号：临 2026-007 无锡市太极实业股份有限公司 关于子公司十一科技项目预中标公示的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要事项提示： ●截至目前，项目尚处于中标人公示阶段，联合体最终能否获得中标通知书 仍存在一定的不确定性。如能确定中标并签订正式合同，因项目存在跨年实施， 且受合同签订时间、开工日期及实施进度影响，对公司 2026 年度业绩的影响存 在不确定性。 一、预中标项目概况 1、招标人：华虹宏力半导体（无锡）有限公司； 近日，无锡市太极实业股份有限公司（以下简称"公司"）子公司信息产业 电子第十一设计研究院科技工程股份有限公司（以下简称"十一科技"）与上海 建工四建集团有限公司（以下简称"上海四建"）组成联合体，参与了华虹宏力 半导体（无锡）有限公司的华虹 FAB9B 项目工程总承包（以下简称"项目"）的 投标。根据无锡市公共资源交易中心发布的《无锡市工程建设项目中标人公示（编 号：WXXQ202601001-X01）》（https://g ...

每经AI快讯，2月5日，太极实业（600667）公告称，近日其子公司十一科技与上海四建组成的联合 体，预中标华虹宏力半导体(无锡)有限公司华虹FAB9B项目工程总承包，投标报价37.78亿元。预计十一 科技合同工作量占比98.46%，对应金额约37.19亿元，以上仅为估算。截至目前，项目尚处中标人公示 阶段，最终能否中标有不确定性，若中标，对2026年度业绩的影响也不确定。 ...

太极实业公告称，子公司十一科技及十一科技海门分公司因建设工程分包合同纠纷，被南通华中建筑安 装工程有限公司起诉，涉案金额含工程款1108.14万元及资金占用损失。截至公告披露日，该案件已受 理，尚未开庭。自前次披露相关公告后，公司及控股子公司连续十二个月内未披露的诉讼和仲裁事项累 计涉案金额8.58亿元，占最近一期经审计净资产的10.09%。部分案件未结案，对利润影响尚不确定。 ...